Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Stock Climbs 13 Percent on New Patent Win

NEW YORK (GenomeWeb News) – Shares in Accelr8 were up 13.17 percent, or $.27, at $2.32 in mid-afternoon trading after the company said it won a US patent that covers devices that use its OptiChem surface chemistry, including those for patient specimen collection and analytical products.
 
Accel8 said U.S. Patent 7,067,194 also covers coating variations not specifically included in prior patents.
 
Accelr8 previously licensed certain OptiChem applications to other companies in the biomedical industry. The firm is now developing its BACcelr8r rapid bacterial diagnostic system that will use OptiChem in its single-use analytical cassette.
 
In addition, Accelr8 said it plans to develop related disposable products for handling patient specimens prior to analysis.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.